RE: The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors19 Feb 2023 15:51
This sounds like the Dox resistance of cancer cells that I came across a few weeks ago. Papers going back 20 years. I wondered if AVA6k could be beneficial to overcoming this resistance and why I had not read about it before. It really sounds like a good opportunity for AVA6k to peel back the resistance layers on a daily basis, rather than 3 weeks between doses. Maybe one day Avacta will disclose something about this.